The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Intellia Therapeutics Inc shares valued at $75,778 were sold by BASTA JAMES on Mar 04 ’24. At $32.99 per share, BASTA JAMES sold 2,297 shares. The insider’s holdings dropped to 81,571 shares worth approximately $2.03 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Clark Eliana sold 605 shares, netting a total of over 19,959 in proceeds. Following the sale of shares at $32.99 each, the insider now holds 71,470 shares.
Before that, Sepp-Lorenzino Laura had sold 2,275 shares from its account. In a trade valued at $65,682, the EVP, Chief Scientific Officer traded Intellia Therapeutics Inc shares for $28.87 each. Upon closing the transaction, the insider’s holdings decreased to 2,275 shares, worth approximately $1.09 million.
As published in a research note from Goldman on February 23, 2024, Intellia Therapeutics Inc [NTLA] has been rated down from a Buy to a Neutral and the price target has been revised to $32 from $136. Analysts at Wolfe Research started covering the stock with ‘”a Peer perform”‘ outlook in a report released in mid February. As of April 13, 2023, Canaccord Genuity has initiated its “Buy” rating for NTLA. Earlier on March 21, 2023, Bernstein initiated its rating. Their recommendation was “an Outperform” for NTLA stock.
Analyzing NTLA Stock Performance
During the last five days, there has been a drop of approximately -4.93%. Over the course of the year, Intellia Therapeutics Inc shares have dropped approximately -18.40%. Shares of the company reached a 52-week high of $34.87 on 02/29/24 and a 52-week low of $19.37 on 04/26/24. A 50-day SMA is recorded $24.66, while a 200-day SMA reached $28.95. Nevertheless, trading volume fell to 1.44 million shares from 1.11 million shares the previous day.
Support And Resistance Levels for Intellia Therapeutics Inc (NTLA)
According to the 24-hour chart, there is a support level at 24.38, which, if violated, would cause prices to drop to 23.89. In the upper region, resistance lies at 25.67. The next price resistance is at 26.47. RSI (Relative Strength Index) is 51.47 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.37, which suggests the price will decrease in the coming days. Percent R is at 51.88%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
